Abstract Prothrombin (F2) 20210G [A [rs1799963 G[A] mutation is a genetic variant which predisposes to inherited thrombophilia. Highest prevalence of this rare mutation has been reported among Caucasian and Mediterranean populations with thrombophilic conditions compared to healthy controls. It is absent or occurs in a very low frequency in both thrombophilic patients and healthy controls of most South Asian populations. A previous study has demonstrated that the mutant allele is absent among Sri Lankan healthy controls. This study was conducted to determine the prevalence of the F2 20210G[A mutation among Sri Lankan patients with thrombo-embolic disorders. F2 20210G[A mutation analysis was carried out on 825 patients. These included 374 with arterial thromboembolic disorders, 303 with venous thromboembolic disorders (VTE) and 148 with pregnancy related complications. Genotyping was done using polymerase chain reaction followed by restriction fragment length polymorphism. The overall prevalence of the individuals detected with the mutation was 0.8 % (7/825) with a mutant allele frequency of 0.4 % (7/1,650), and all were heterozygotes. Further classification according to the types of thrombotic events showed a prevalence of 0.5 % (2/ 374), 1.3 % (4/303), and 0.7 % (1/148) respectively, in the three groups with arterial thrombosis, VTE and pregnancy complications. The respective mutant allele frequencies in the three different groups were 0.3 % (2/748), 0.7 % (4/ 606) and 0.3 % (1/296). Although these figures are lower than that of Caucasian and Mediterranean populations, they are relatively higher compared to other South Asian populations. Therefore, the F2 20210G[A mutant allele is not entirely absent among Sri Lankan patients with thromboembolic disorders.
Introduction
Thrombophilia is a multifactorial disorder of inappropriate clot formation which can be caused due to an interaction of genetic, acquired, and/or circumstantial predisposing factors. Venous thromboembolism (VTE) most commonly manifests as deep vein thrombosis, which may progress to pulmonary embolism if the clot dislodges and travels to the lungs. Other thrombotic manifestations include thrombosis of the cerebral or visceral veins, arterial thrombotic events such as cerebrovascular accidents, myocardial infarctions and pregnancy related complications such as pre-eclampsia and recurrent pregnancy losses [1] [2] [3] . Hypercoagulability that causes thrombophilia can be either inherited or acquired. The substitution of nitrogenous base G (Guanine) by A (Adenine) at position 1691 (1691G[A) in the Factor V gene [factor V Leiden] (rs6025), the substitution of G to A at position 20210 (20210G[A) (rs1799963) in the Prothrombin (Factor II/F2) gene and the homozygous substitution of C (Cytosine) by T (Thymine) at position 677 (677C[T) (rs1801133) in the 5, 10-methylenetetrahydrofolate reductase (MTHFR) gene are the most common causes of inherited thrombophilia [1, 4] . In most inherited thrombophilias, impaired neutralization of thrombin or a failure to control the generation of thrombin causes thrombosis [1] .
Prothrombin encoded by the F2 gene, is a central regulatory component of the coagulation cascade which in its active form, thrombin, performs both procoagulant and anticoagulant roles [5, 6] . The prothrombin F2 20210G[A mutation located at the 3 0 cleavage site of the mRNA of the F2 gene results in elevated plasma prothrombin levels and an increased risk of thrombosis [6] . This variant has been shown to directly influence a variety of processes related to prothrombin mRNA metabolism such as prothrombin premRNA cleavage, polyadenylation, mRNA stability and translation [6] [7] [8] [9] [10] .
According to a review by Jadaon [11] , the prevalence of the individuals having F2 20210G[A mutation, ranges from 3 to 17 % in patients with VTE and 1 to 8 % in healthy controls among Caucasians [11] . High prevalence of this mutation has also been reported in populations living close to Europe, mainly in the Middle East and North Africa. The prevalence in these countries is similar to that reported in South European countries which is approximately 3 to 24 % in VTE patients and 1 to 12 % in the general population [11] . Previous studies have reported the absence of this mutation among healthy controls in Asian populations in China, Japan, Korea, Mongolia, Taiwan, Indonesia, Burma, Cambodia, Thailand, Taiwan, Vietnam, Hong Kong, Pakistan and Bangladesh [11, 12, [15] [16] [17] [18] [19] [21] [22] [23] [24] [25] , while in India it was reported to be between 0 to 0.6 % [11, 19, 22, [25] [26] [27] [28] [29] . Among the VTE patients in China, Korea, and Taiwan, the prevalence of the mutation carriers was 0 % [11, 12, [15] [16] [17] [19] [20] [21] [22] [23] [24] . Even among the Indian VTE patients, the prevalence was 0 % [11, 19, 22, [25] [26] [27] [28] [29] . Hence it is likely that the F2 20210G[A mutation occurs in a very low frequency in Asian and other non Caucasian populations [11, 12] . A study conducted by Dissanayake et al. [13] Genomic DNA was extracted using Wizard genomic DNA purification kit (Promega, USA) according to the manufacturer's protocol. Extracts were subjected to gel electrophoresis using 1 % agarose gel to confirm the presence of DNA. The mutation was detected using the routine polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method carried out at the human genetics unit. It was a duplex PCR for the F2 20210G[A and FV 1691G[A mutations adapted from a previously described method by Koksal et al. in 2007 [14] . The PCR was followed by RFLP assay based on MnlI endonuclease digestion.
The PCR reaction was performed in a total volume of 25 ll containing 19 buffer (Promega, USA), 2.0 mmol/l MgCl 2 , 0.2 mmol/l dNTPs, 0.4 lmol/l of each F2 primer, 0.8 lmol/l of each FV primer and 5 units of Taq DNA polymerase (Promega, USA). The PCR cycling conditions included initial denaturation of 5 min at 94°C followed by 35 cycles with 30 s at 94°C, 30 s at 60°C, 30 s at 72°C and a final extension of 10 min at 72°C as described in the original article [14] . This PCR amplifies a 169-bp product form exon 10 of FV and a 221-bp product from the 3 0 untranslated region of F2 gene [14] . From the PCR product, 10 ll was digested with 5 units of MnlI in 19 solution of its buffer. After the digestion, the F2 amplicon with the mutant allele was supposed to remain undigested while the wild type allele provides one digestion site to yield two products of 29-bp and 192-bp. The FV amplicon with the wild type allele was digested into three products of 17-bp, 37-bp and 115-bp while the mutant allele containing amplicon was digested into two: 17-bp and 152-bp. Digested amplicons were visualized after gel-electrophoresis on a 3 % agarose gel incorporated with ethidium bromide. A gel image with the wild type and mutant bands of F2 and FV is shown in Fig. 1 . The positive controls in each genotyping batch had been sequenced by Sanger sequencing and confirmed. The two double heterozygotes for the FV1691 G[A and F2 20210 G[A mutations were also confirmed by Sanger sequencing.
Results
The total number of patients tested was 825. Of them, 340 (41.2 %) were males and 485 (58.8 %) were females. The ethnicity of the study population comprised of Sinhalese (85 %), Tamils (6 %) and Moors (5 %). In 4 % of the patients the ethnicity was not documented. The ages of the patients ranged from 1 to 77 years. The distribution of the patients tested, according to the indication for referral is shown in Table 1 .
The prevalence of individuals with the F2 20210G[A mutation in this cohort was 0.8 % (7/825). Six of the positive cases were Sinhalese and one case was a Moor. All were heterozygotes for the mutation and no homozygotes were found. Among them, 0.6 % (5/825) had only the F2 20210 G[A mutation while 0.2 % (2/825) were double heterozygotes for the FV 1,691 G[A and F2 20210 G[A mutations. The mutant allele frequency in this cohort of patients was 0.4 % (7/1650). The results were further analyzed after categorizing the patients into three groups according to the types of thrombotic events. It showed that among the patients with arterial thrombosis, the prevalence of the individuals who have the mutation was 0.5 % (2/ 374); 1.3 % (4/303) in those with VTE. Among the patients with pregnancy related complications, it was 0.7 % (1/ 148). The respective mutant allele frequencies in the three groups were 0.3 % (2/748), 0.7 % (4/606) and 0.3 % (1/ 296). Screening of asymptomatic family members of some of the index patients was also carried out. The clinical details of the patients who were heterozygotes for the F2 20210G[A mutant allele and the results of asymptomatic family members who were tested are summarized in Table 2 .
Discussion
In patients with thrombo-embolic events, inherited thrombophilia is suspected when the patient has recurrent or lifethreatening venous thromboembolism, family history of venous thrombosis, thrombo-embolic events in patients aged less than 45 years of age, without apparent acquired risk factors or in females with a history of multiple miscarriages, stillbirths, or both. Although inherited thrombophilia is often suspected in such cases, both acquired and genetic factors may frequently co-interact, thus making it difficult to decide whether the patient should undergo screening tests for inherited factors such as F2 and FV mutations [30] .
The substitution of adenine for guanine at nucleotide position 20210 of the Prothrombin gene (F2 20210G[A) was first described as a cause of inherited thrombophilia by Poort et al. [31] in 1996. They described the 20210G[A mutation found in the 3 0 untranslated region of the Prothrombin gene as a moderate risk factor for venous thrombosis. The risk of developing VTE is increased even in the presence of a heterozygous F2 20210G[A mutation. This mutation is found to be associated with an increased level of plasma prothrombin. The mechanism which upregulates the plasma prothombin level is not clearly known [31] . This increased level of prothombin promotes the generation of thrombin [30, 32, 33] , which in turn increases the risk of developing venous thrombosis by almost threefold in patients of all ages [31] . This risk is slightly lower than that for FV 1691G[A [FV Leiden] heterozygotes who have a 3-8 fold increased risk and significantly lower than that for FV Leiden homozygotes who have an almost 80 fold increased risk [34] . Although F2 20210G[A is one of the common genetic risk factors causing inherited thrombophilia in white Caucasians, it is less reported in Asians and Africans [30] . A large metaanalysis by Gohil et al. [35] confirmed a significant According to their report, the smaller sample sizes tested in non-European populations make definitive conclusions about the genetic aetiology of VTE less reliable in those groups [35] . Another pooled analysis of several case control studies by Emmerich et al. [34] has demonstrated a significant increase in venous thrombosis in double hererozygotes for FV 1691G[A and F2 20210G[A mutations than in those with a single mutation. Furthermore, it was reported that the double heterozygotes had thrombosis at a significantly younger age compared to the rest [34] . Other than FV Leiden, another mutation: F2 19911A[G found in the same gene has also been described as a risk factor which slightly increases the risk of venous thrombosis when co-exists with the F2 20210G[A mutation [36] .
Studies conducted among different racial groups have confirmed varying prevalences of the individuals with F2 20210G[A mutation. The highest prevalence of F2 20210G[A mutation has been reported among Caucasians of European origin and Mediterranean populations living close to Europe. Furthermore, the prevalence of the mutation in those populations is higher among patients with thromo-embolic disorders than in healthy controls [11, 12] . However, in many Asian countries it is reported to be absent in both the healthy controls as well as among patients with thrombo-embolic disorders [11, 12, [15] [16] [17] [18] [19] [21] [22] [23] [24] [25] . Even in India, only one study has reported a prevalence of 0.6 % among healthy controls [22] , while some other studies have reported it as 0 % [11, 19, [25] [26] [27] [28] [29] . The mutation has not been reported among Indian patients with venous thrombo-embolism [11, 19, 22, [25] [26] [27] [28] [29] . These studies suggest that the F2 20210G[A mutation may not be a significant genetic risk factor predisposing to inherited thrombophilia in those populations.
In 2009, a study was conducted by Dissanayake et al. to determine the F2 20210G[A mutant allele frequency among healthy controls in the Sri Lankan population. They reported that the mutation was absent among healthy controls across all the three ethnic groups (Sinhala, Tamil and Moor) in Sri Lanka [13] . The present study was undertaken to determine the prevalence of the F2 20210G[A mutation among Sri Lankan patients with thromboembolic disorders. In contrast to most reports from other Asian populations, we found that the mutation was not entirely absent among these patients as 0.8 % were heterozygotes for the mutation with a mutant allele frequency of 0.4 %. If the VTE group alone is considered, the prevalence of Sri Lankan VTE patients having this mutation was 1.3 % (with a mutant allele frequency of 0.7 %). This is higher than almost all the VTE groups that have been studied in South and Southeast Asia. The arterial thrombosis group in this study had 2 (0.5 %) patients with a heterozygous mutation. Although significantly associated with VTE [31] , the role of F2 20210G[A in arterial vascular diseases is not very clear [37, 38] . Rosendaal et al. [39] showed that it increases the risk of myocardial infarction in young women aged 18 to 44 years [38, 39] . Such an association was not detected among men [38, 40] . In our study, both the arterial thrombotic patients detected with the F2 20210G[A mutation were males who had cerebro-vascular accidents. One of them was a double heterozygote for the F2 20210G[A and FV Leiden mutations. Although the other patient did not have the FV Leiden mutation, there is a possibility that he may have some other genetic risk factors known to increase the risk of arterial thrombosis such as polymorphisms in fibrinogen [41] and Factor VII genes [42] or elevated levels of homocysteine due to mutations in genes regulating the methionine-homocysteine pathway [43] . Findings of this study suggest that the F2 20210G[A screening should not be abandoned from Sri Lankan test panels for genetic thrombophilia as it is not completely absent among Sri Lankan VTE patients. More case-control studies are required in order to confirm the significance of F2 20210G[A as a genetic risk factor among Sri Lankans. Furthermore, the prevalence, allele frequencies and the association of other genetic risk factors i.e. MTHFR 677C[T, FV 1691G[A, FV 4070A[G, and F2 11991G[A polymorphisms should also be studied in order to determine the mutations that should be selectively incorporated into the Sri Lankan genetic thrombophilia test panels. 
